NEW YORK (TheStreet) -- Amicus Therapeutics (FOLD - Get Report) surged Tuesday after the company announced its lead drug migalastat was effective in treating patients with Fabry disease in a late-stage trial.
Amicus found the drug effective in patients after 12 months of treatment in the trial, which tested migalastat as a form of monotherapy in patients with Fabry disease, a disorder in which a fat called globotriaosylceramide builds up in the body's cells. The company also released positive 24-month data.
"Today is a great day for Amicus and the Fabry community," said Chairman and CEO John F. Crowley in a statement. "Pending positive data from our second Phase 3 study we expect to meet with regulatory authorities to discuss these data and determine the fastest registration pathway for migalastat."
Must Read: Warren Buffett's 10 Favorite Growth StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was up 21.74% to $2.24 at 2:04 p.m. STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.